Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5907 - Liquid biopsy concordance based on clonality and timing of testing in patients with metastatic colorectal cancer

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Pashtoon Kasi

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

P.M. Kasi1, S. Kamatham2, F. Shahjehan2, Z. Li3, P.W. Johnson3, A. Merchea4, D.T. Colibaseanu4

Author affiliations

  • 1 Hematology/oncology, Holden Comprehensive Cancer Center, University of Iowa, 52242 - Iowa City/US
  • 2 Hematology/oncology, Mayo Clinic, 32224 - Jacksonville/US
  • 3 Biostatistics, Mayo Clinic, 32224 - Jacksonville/US
  • 4 Colorectal Surgery, Mayo Clinic, 32224 - Jacksonville/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5907

Background

The most recent consensus statement on the use of liquid biopsies (circulating tumor DNA – ctDNA testing) has been that it is not yet ready for prime time. However, in patients with metastatic colorectal cancer (mCRC), there is significantly more ‘shedding’ of DNA detectable in blood allowing this test to be of value. We aimed at reporting the concordance of liquid biopsies based on clonality and timing of testing in patients with mCRC.

Methods

A total of 92 mCRC patients were identified who had both a commercially available liquid and tissue next generation sequencing assay done from December 2016 to February 2019. Arbitrarily, mutations were classified as clonal or subclonal based on the 50% cutoff of the highest variant allele frequency (VAF) reported. Concordance rates, including clonal (BRAF-V600E/ RAS), subclonal and amplification concordance were calculated separately for patients for whom the liquid biopsy testing was done before initiation of treatment (n = 27) and after initiation of treatment (n = 65).

Results

Clonal concordance rates were 96.3% for patients when the liquid biopsy was done before initiation of treatment versus 64.6% for patients when the test was obtained after they were already on some systemic therapy (p value: 0.001). Similarly, subclonal and amplification concordance rates for patients in the test before treatment and test after treatment groups are summarized in the table. Moreover, the median of highest VAF% was noted to be 3.1% and 1.1% in test before treatment and test after treatment groups respectively (p value: 0.092).Table:

622P Summary of concordance rates by timing of liquid biopsy test

Test before treatment (N = 27)Test after treatment (N = 65)Total (N = 92)P value
*Clonal Concordance26: 96.3 (81.0, 99.9)42: 64.6 (51.8, 76.1)68: 73.9 (63.7, 82.5)0.001
BRAF27: 100.0 (87.2, 100.0)64: 98.5 (91.7, 100.0)91: 98.9 (94.1, 100.0)1.000
RAS26: 96.3 (81.0, 99.9)52: 80.0 (68.2, 88.9)78: 84.8 (75.8, 91.4)0.058
Subclonal Concordance21: 77.8 (57.7, 91.4)44: 67.7 (54.9, 78.8)65: 70.7 (60.2, 79.7)0.452
BRAF27: 100.0 (87.2, 100.0)65: 100.0 (94.5, 100.0)92: 100.0 (96.1, 100.0)1.000
RAS27: 100.0 (87.2, 100.0)62: 95.4 (87.1, 99.0)89: 96.7 (90.8, 99.3)0.553
Amplification Concordance22: 81.5 (61.9, 93.7)41: 63.1 (50.2, 74.7)63: 68.5 (58.0, 77.8)0.092
Highest Variant Allele Frequency (VAF)%3.1 (0.0, 84.6)1.1 (0.0, 90.1)1.5 (0.0, 90.1)0.092

Concordance rates are summarized by count: percent (95% binomial confidence interval). P values arise from Fisher’s exact tests; *Arbitrarily, 50% of the highest variant allele frequency (VAF)% value in the liquid biopsy results has been used to differentiate clonal from subclonal mutations. Highest VAF% is summarized by median (range). P values arise from Wilcoxon rank sum test

Conclusions

Liquid biopsies show a very high concordance rate in patients with metastatic colorectal cancer. It is important to take the timing of the assay into consideration alongside relevant clonal mutations while assessing the concordance of liquid biopsies, not just for mCRC but for other malignancies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.